Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.

Villena SN, Pinheiro RO, Pinheiro CS, Nunes MP, Takiya CM, DosReis GA, Previato JO, Mendonça-Previato L, Freire-de-Lima CG.

Cell Microbiol. 2008 Jun;10(6):1274-85. doi: 10.1111/j.1462-5822.2008.01125.x. Epub 2008 Jan 30.

PMID:
18284419
2.

Cryptococcus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway.

Chiapello LS, Baronetti JL, Garro AP, Spesso MF, Masih DT.

Int Immunol. 2008 Dec;20(12):1527-41. doi: 10.1093/intimm/dxn112. Epub 2008 Oct 16.

PMID:
18927317
3.

Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.

Pericolini E, Cenci E, Monari C, De Jesus M, Bistoni F, Casadevall A, Vecchiarelli A.

Cell Microbiol. 2006 Feb;8(2):267-75.

PMID:
16441437
4.

Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators.

Ellerbroek PM, Walenkamp AM, Hoepelman AI, Coenjaerts FE.

Curr Med Chem. 2004 Jan;11(2):253-66. Review.

PMID:
14754421
5.

The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction.

McFadden DC, De Jesus M, Casadevall A.

J Biol Chem. 2006 Jan 27;281(4):1868-75. Epub 2005 Nov 8.

6.
7.

Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

De Jesus M, Nicola AM, Rodrigues ML, Janbon G, Casadevall A.

Eukaryot Cell. 2009 Jan;8(1):96-103. doi: 10.1128/EC.00331-08. Epub 2008 Oct 24.

8.

Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans.

Grijpstra J, Gerwig GJ, Wösten H, Kamerling JP, de Cock H.

Eukaryot Cell. 2009 Aug;8(8):1165-73. doi: 10.1128/EC.00013-09. Epub 2009 Jun 19.

9.

Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy.

Vecchiarelli A, Pericolini E, Gabrielli E, Chow SK, Bistoni F, Cenci E, Casadevall A.

Immunotherapy. 2011 Aug;3(8):997-1005. doi: 10.2217/imt.11.86. Review.

PMID:
21843086
10.
11.

In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.

Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR.

J Infect Dis. 2001 Aug 15;184(4):479-87. Epub 2001 Jul 13.

PMID:
11471106
13.

Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages.

Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, Vecchiarelli A.

J Immunol. 2005 Mar 15;174(6):3461-8.

14.
15.
16.

Glucuronoxylomannan of Cryptococcus neoformans exacerbates in vitro yeast cell growth by interleukin 10-dependent inhibition of CD4+ T lymphocyte responses.

Mariano Andrade R, Monteiro Almeida G, Alexandre DosReis G, Alves Melo Bento C.

Cell Immunol. 2003 Apr;222(2):116-25.

PMID:
12826081
17.

Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.

Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE.

Infect Immun. 1991 Oct;59(10):3700-7.

18.

Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans.

Jesus MD, Nicola AM, Chow SK, Lee IR, Nong S, Specht CA, Levitz SM, Casadevall A.

Virulence. 2010 Nov-Dec;1(6):500-8. Epub 2010 Nov 1.

19.

Tumor necrosis factor-inducing activities of Cryptococcus neoformans components.

Delfino D, Cianci L, Migliardo M, Mancuso G, Cusumano V, Corradini C, Teti G.

Infect Immun. 1996 Dec;64(12):5199-204. Erratum in: Infect Immun 1997 May;65(5):1991.

20.

Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

van de Wetering JK, Coenjaerts FE, Vaandrager AB, van Golde LM, Batenburg JJ.

Infect Immun. 2004 Jan;72(1):145-53.

Supplemental Content

Support Center